

Press release – For immediate release July 15th, 2019 – 5:45 PM CEST

Half year Median Technologies liquidity contract statement contracted with AUREL BGC Company

Sophia Antipolis, France – Under the liquidity contract entrusted by Median Technologies to AUREL BGC, the following resources were listed in the liquidity account as of June 30, 2019:

- €104,740.61
- 43,401 shares
- Transactions during the first half 2019:

BUY	47,949 shares	€70,887.89	126 transactions
SELL	54,182 shares	€81,725.67	126 transactions

For information, as of December 31, 2018, the following resources were listed in the liquidity account:

- € 93,902.83
- 49,634 shares



About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors

and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label "Innovative company" by the BPI and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). For more information: www.mediantechnologies.com

Contacts

Median Technologies	Press - ALIZE RP	Investors - ACTIFIN
Emmanuelle Leygues	Caroline Carmagnol /Aurore	Ghislaine Gasparetto
Head of Corporate Communications	Gangloff	+33 1 56 88 11 11
+33 6 10 93 58 88	+ 33 6 49 57 82 68	ggasparetto@actifin.fr
emmanuelle.leygues@mediantechnologies.com	median@alizerp.com	